PubMed Health⌕ Search

Biomedical subjects

F Lonardi

Publications and source records attributed to F Lonardi.

17 recordsLinked to original sources
PubMed2001

Preoperative, single-fraction irradiation for prophylaxis of heterotopic ossification after total hip arthroplasty.

We gave a single fraction of 750 cGy preoperatively (within 16 h of surgery) to 143 patients prior to total hip arthroplasty. The patients were evaluated for heterotopic ossification at 1, 3 and 6 months. The preoperative radiation did not affect the surgical procedure. After a median follow-up of 12 (6-24) months we encountered six patients with heterotopic ossifications of Brooker grade I-II. Potential late risks from ionising radiation should be considered when treating younger patients.

Adult↗
PubMed2000

Radiotherapy for non-small cell lung cancer in patients aged 75 and over: safety, effectiveness and possible impact on survival.

For patients with advanced, inoperable non-small cell lung cancer (NSCLC), increasing age seems to be the primary reason of receiving no treatment. The elderly aged 75 years and over are more likely to be given only supportive care (irrespective of symptoms) or no therapy at all. We evaluated the outcome of 48 patients, aged 75 years and over, treated with radiation therapy for advanced (stage IIIA-B), inoperable, symptomatic NSCLC. A median dose of 50 Gy was delivered to the primary site and mediastinum with standard fractionation. Based on WHO criteria, of 47 assessable patients, 21 had partial remission, 17 stable disease, and nine had progressive disease. Most symptoms were successfully palliated. Toxicity was negligible and mainly consisted of WHO grade I-II esophagitis. Despite the overall median survival being short (5 months), dose-related survival was much better in patients given at least 50 Gy than in those treated with lower doses: 52% versus 35% at 6 months, and 28% versus 4% at 13 months. These results confirm that radiation therapy may be safely delivered to very aged patients with advanced NSCLC at not merely palliative doses, both to achieve better local control and to give likely survival benefits. Adequate pretreatment evaluation should be always performed to exclude any comorbidity unfit to chest radiation and to individualize treatment to the single patient requirements. Because a large amount of literature data now concurs with the feasibility and safety of high-dose radiotherapy in the elderly, specifically designed, age-oriented trials are needed to settle definitively the issue of survival advantage from curative radiotherapy in these patients.

Aged↗
PubMed1996

Evaluating the impact of radiotherapy on the quality of life of cancer patients by two simple indexes. A pilot study.

The subjective chemotherapy impact (SCI) test has been widely used to evaluate the quality of life in patients receiving chemotherapy. In this study we have tested the SCI questionnaire as an index of the impact of radiotherapy on quality of life. A group of 25 consecutive cancer patients treated with radiotherapy in our centre were tested. In the first item patients were asked to state the number of days they spent with "discomfort". The second item asked them which days they would like to eliminate altogether because of the unbearable symptoms experienced. SCI questions were asked by the same physician before the start of radiotherapy, at the mid point, at the end and 4 months later. A preliminary assessment of validity and reliability of these two indexes provided satisfactory results; data allowed a clear and discriminating differentiation between patients treated with palliative curative radiotherapy and patients who received "adjuvant" treatment (radiotherapy worsened the quality of life in the latter group).

Adolescent↗
PubMed1989

4'epidoxorubicin plus verapamil in anthracycline--refractory cancer patients.

Four patients refractory to doxorubicin (DX) and 9 patients refractory to 4'epidoxorubicin (4'EpiDX) were treated with verapamil (VRP) (120 mg every 6 h for 3 days) plus 4'EpiDX (80 mg/m2 i.v. bolus, together with the 6th VRP administration). Three patients had partial remissions lasting 3, 3.5 and 7 months, respectively. Toxicity grading did not exceed usual levels. The study demonstrates that VRP, when added at conventional doses to 4'EpiDX, can induce objective responses in some patients refractory to anthracyclines.

Adult↗
PubMed1989

Factors causing dose variability in drug administration.

The variability of the drug dose actually given to cancer patients was analyzed. Three variability factors were quantitatively examined (body surface calculation, personalized dose calculation, and drug residuum in commercially available vials) and their variability was experimentally measured. A systematic reduction (mean, 7%; range, 2%-15%) and a random variability (4%-5%) of the dose given were demonstrated. These results draw attention to the role of some of the procedures of routine clinical activity in determining the amount of drug actually delivered. The analysis suggests that personalization of doses must be very accurate in both measurement and calculation and that the staff giving the drug needs to be carefully informed about the importance of drug residuum. The variability of the delivered dose can lead to the misclassification of patients in investigations on the dose-response relationship. This factor may be added to pitfalls previously reported to affect this type of retrospective analysis.

Antineoplastic Agents↗
PubMed1989

[Peripheral lymphocyte populations in patients treated with pelvic and mediastinal radiotherapy].

Solid tumor bearing patients often show a large variety of immunologic alterations: increase in immune complexes number, reduced NK activity, decreased IL-2 production, T4/T8 reverse and s.o. Most literature data generally concern chemotherapy and/or radiotherapy pretreated patients, so it is difficult to relate the immunological alterations with either antineoplastic treatments or the disease itself. We tried to evaluate any possible alteration of immunological parameters in patients with solid neoplasms who underwent radiotherapy on mediastinum or pelvis. The aim was to detect any variation in peripheral lymphoid sub-populations (even per site of irradiation) and a possible activation of an immune therapy. The evaluable patients were 38 (12 treated with surgery). The minimum dose delivered was 5000 cGys through conventional fractionation. The immunological parameters (T, B, N, T4, T8, H/S) were evaluated before the treatment, at the end and every 2 months during follow-up. Cases were analyzed also per single irradiation volume. No statistically significant variation in immunological parameters was found, although suppressor activity was confirmed as prevailing in immune responsiveness of cancer patients. Thus any significant correlation between immunological state and disease evolution or response to treatment has still to be verified.

Adult↗
PubMed1988

Bleomycin, vincristine, mitomycin and cisplatin alternated with cyclophosphamide, 4'-epidoxorubicin and procarbazine in advanced non-small-cell lung cancer.

Thirty-eight patients with histologically confirmed non-small-cell lung cancer were treated with bleomycin, vincristine, mitomycin and cisplatin (BOMP) alternated with cyclophosphamide, 4'-epidoxorubicin and procarbazine (CEP). Twenty patients were randomized to start the treatment with BOMP and 18 with CEP. Patients underwent a median of 4 cycles (range, 1-8). The overall response rate was 36% with 2 clinical complete responses. The median duration of response was 6.5 months, the median survival time was 7.5 months, and 37% of patients survived for more than one year. The comparison between the two arms of this study and between this study and a previous investigation on the effectiveness of BOMP suggests that CEP regimen added to BOMP does not significantly improve patient outcome.

Adult↗
PubMedDate not supplied

Primary lymphoma of the vagina. A case report.

Primary vaginal non-Hodgkin lymphoma is really uncommon and may be misdiagnosed as inflammatory disease or solid cancer, so careful diagnostic procedures are needed, particularly as far as pathological and immunocytochemical evaluation is concerned. Most of these lymphomas present with follicular patterns and limited stage disease, so high cure rates are possible with surgery and/or radiotherapy, but chemotherapy has to be considered on the basis of clinical presentation and pathologic features. We report a case of vaginal lymphoma with primary bulky ulcered mass hat was treated with chemoradiotherapy.

Female↗
PubMedDate not supplied

Survey on the use of questionable methods of cancer treatment. GOCS. Grupo Oncólogico Cooperativo del Sur República Argentina.

BACKGROUND: Despite the improvement of cancer treatments, unproven and useless therapies are widely adopted among cancer patients and their families. Little information is available on the actual magnitude of such a phenomenon. METHODS: Two anonymous, similarly aimed surveys were independently carried out in Italy and Argentina on cancer patients and their families by two research groups. RESULTS: Respectively 563 and 400 questionnaires were distributed. The percentage of patients and/or families involved in unsound care (17%) was similar in both surveys. Of these treatments, 20%-38% were proposed by physicians, but relatives, friends, and mass-media had an equally important role. The costs of such care was difficult to estimate. CONCLUSIONS: Real and exhaustive efforts are needed by Health Care Organizations, which must execute a policy of information and education towards the public and professionals, as well as declare unethical the use of unproven therapies which claim cancer cure but simply create false hopes. All oncologists should be aware of the use of these treatments for cancer patients, even concomitantly with conventional care.

Humans↗
PubMedDate not supplied

Radiation therapy of bone metastases in the elderly: a multicentric survey of the Italian "Geriatric Radiation Oncology Group".

External radiation therapy (ERT) has been reported to be the elective treatment of symptomatic bone metastases. A nationwide survey on the use of ERT in elderly patients with bone metastases has been conducted by the Italian "Geriatric Radiation Oncology Group" with a three-fold aim: define the state of the art of ERT, evaluate the analgesic efficacy and identify the optimal dosage and schedule, if any. 347 patients aged 70 or over, treated in 29 different institutions for a period of six months were analyzed. Conclusive results were: a significant pain relief achieved shortly after ERT completion; an improvement in the quality of life; a decrease in the dose of analgesics and consequently, a reduction in treatment-related costs. Unfortunately the optimal treatment schedule remains unidentified; ERT was neither aggressive nor toxic in this series of elderly patients.

Aged↗